NeuroBo PharmaceuticalsNRBO
Market Cap: $27.7M
About: NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
984% more capital invested
Capital invested by funds: $398K [Q1] → $4.32M (+$3.92M) [Q2]
13.73% more ownership
Funds ownership: 2.01% [Q1] → 15.73% (+13.73%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
8% less funds holding
Funds holding: 13 [Q1] → 12 (-1) [Q2]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for NRBO.